A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Public ClinicalTrials.gov record NCT05984277. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Study identification
- NCT ID
- NCT05984277
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 895 participants
Conditions and interventions
Conditions
Interventions
- Volrustomig Drug
- Pembrolizumab Drug
- Carboplatin Drug
- Paclitaxel Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2023 (Actual)
- Primary completion
- Aug 17, 2026 (Actual)
- Completion
- Nov 12, 2027 (Estimated)
- Last update posted
- Oct 9, 2026
2023 – 2027
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Hot Springs | Arkansas | 71913 | — |
| Research Site | Springdale | Arkansas | 72762 | — |
| Research Site | Long Beach | California | 90806 | — |
| Research Site | Lone Tree | Colorado | 80124 | — |
| Research Site | Orlando | Florida | 32827 | — |
| Research Site | St. Petersburg | Florida | 33705 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Des Moines | Iowa | 50309 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Grand Island | Nebraska | 68803 | — |
| Research Site | Lincoln | Nebraska | 68506 | — |
| Research Site | Omaha | Nebraska | 68130 | — |
| Research Site | East Syracuse | New York | 13057 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Horsham | Pennsylvania | 19044 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Memphis | Tennessee | 38104 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Nashville | Tennessee | 37212 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Irving | Texas | 75063 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 205 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05984277, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05984277 live on ClinicalTrials.gov.